Robeauté, a Paris-based medtech startup growing neurosurgical microrobots, has introduced the completion of a €27.2 million funding spherical to advance their microbot tech, provoke human trials in 2026, and set up operations within the US as the corporate pursues FDA approval.
Led by Plural, Cherry Ventures, and Kindred Ventures, the spherical additionally noticed participation from LocalGlobe, Suppose.Well being, returning investor APEX Ventures, and a strategic funding from Brainlab.
Bertrand Duplat, CEO of Robeauté, remarked: “There’s unexplored potential for microrobots in medication. Present neurosurgery strategies are invasive and might be deadly, while it’s tough for remedy to go the blood-brain barrier and get to its supposed goal. We’re creating microrobots that may carry unparalleled entry to the mind with personalised, precision medication that may remodel remedies and affected person outcomes.”
The corporate was based by robotics knowledgeable Bertrand Duplat and operations specialist Joana Cartocci in 2017. Duplat brings 30 years of expertise, having labored on robotics for McGill College and the European House Company, and co-founding 3D software program firm Virtools, which was acquired by Dassault Systèmes.
Robeauté’s strategy stems from a deeply private motivation: Duplat’s mom was identified with glioblastoma; a malignant mind tumour.
Neurological issues are notoriously difficult to diagnose and deal with, particularly of their early levels. Present neurosurgical strategies depend on invasive instruments that lack precision and flexibility, whereas many pharmaceutical remedies wrestle to penetrate the blood-brain barrier successfully.
Robeauté’s microrobots, the scale of a grain of rice, are designed to beat these limitations. Able to navigating curved routes by way of the mind’s extracellular matrix, these microrobots can safely entry a number of websites, delivering focused remedies, accumulating samples, or implanting sensors with precision.
Over eight years, their staff has developed a platform boasting greater than 50 patents. The microrobots incorporate cutting-edge applied sciences, together with a tiny engine, propeller, and steering system, enabling surgeons to trace their motion in actual time.
Animal research are underway, specializing in biopsy functions as a precursor to full remedy and monitoring capabilities. Future functions will embody partnerships with industrial and analysis collaborators to unlock the potential for real-time mind intervention and monitoring.
The funding will even facilitate Robeauté’s entry into the US market and help collaboration with Brainlab, whose strategic funding highlights the corporate’s alignment with advancing neurosurgical capabilities.
Robeauté goals to redefine neurosurgery by offering instruments for extra correct diagnostics, focused remedies, and improved affected person outcomes.
Joana Cartocci, COO of Robeauté, said: “We’re constructing the microrobots that may allow a radical paradigm shift in how we strategy neurosurgery and dialogue with the mind. We like to consider our microrobot as a mind gardener, that may are likely to the pathological organ from inside, with a normal service that may be tailored to suit quite a lot of extensions. Our first software is superior biopsy however from there the potential is boundless, unlocked by way of offering protected entry and unprecedented site-specific knowledge. We’re pleased with our European roots and every little thing we now have achieved right here to date. We sit up for the subsequent stage in our firm’s progress as we develop to the US and work carefully with the regulatory authorities to carry the system to sufferers.”
Buyers have expressed robust confidence in Robeauté’s potential. Ian Hogarth, accomplice at Plural, famous: “Robeauté’s know-how doesn’t simply have the potential to rework neurosurgery — it might additionally essentially change how drug firms discover the perfect options for sufferers.” Equally, Filip Dames, Founding Accomplice at Cherry Ventures, highlighted: “The problem posed by neurodegenerative illnesses is immense, touching numerous lives throughout the globe. What Robeauté is constructing actually embodies the spirit of frontier know-how.”
